Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Marjoleen J M A Nijsen; Fan Wu; Loveleena Bansal; Erica Bradshaw-Pierce; Jason R Chan; Bianca M Liederer; Jerome T Mettetal; Patricia Schroeder; Edgar Schuck; Alice Tsai; Christine Xu; Anjaneya Chimalakonda; Kha Le; Mark Penney; Brian Topp; Akihiro Yamada; Mary E Spilker

doi:10.1002/psp4.12282

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):135-146. doi: 10.1002/psp4.12282. Epub 2018 Feb 1.

Authors

Marjoleen J M A Nijsen¹, Fan Wu², Loveleena Bansal³, Erica Bradshaw-Pierce⁴, Jason R Chan⁵, Bianca M Liederer⁶, Jerome T Mettetal⁷, Patricia Schroeder⁸, Edgar Schuck⁹, Alice Tsai¹⁰, Christine Xu¹¹, Anjaneya Chimalakonda¹², Kha Le¹³, Mark Penney¹⁴, Brian Topp¹⁵, Akihiro Yamada¹⁶, Mary E Spilker¹⁷

Affiliations

¹ Abbvie Inc, North Chicago, Illinois, USA.
² Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.
³ GlaxoSmithKline, King of Prussia, Philadelphia, USA.
⁴ Takeda, San Diego, California, USA.
⁵ Eli Lilly and Company, Indianapolis, Indiana, USA.
⁶ Genentech Inc., South San Francisco, California, USA.
⁷ AstraZeneca, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
⁸ Biogen, Cambridge, Massachusetts, USA.
⁹ Eisai Inc, Woodcliff Lake, New Jersey, USA.
¹⁰ Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
¹¹ Sanofi, Bridgewater, New jersey, USA.
¹² Bristol-Myers Squibb, Princeton, New Jersey, USA.
¹³ Agios, Boston, Massachusetts, USA.
¹⁴ UCB, Celltech, Slough, Berkshire, United Kingdom.
¹⁵ Merck & Co., Inc, Kenilworth, New Jersey, USA.
¹⁶ Astellas Pharma Inc., Tokyo, Japan.
¹⁷ Pfizer Worldwide Research and Development, San Diego, California, USA.

Abstract

A cross-industry survey was conducted to assess the landscape of preclinical quantitative systems pharmacology (QSP) modeling within pharmaceutical companies. This article presents the survey results, which provide insights on the current state of preclinical QSP modeling in addition to future opportunities. Our results call attention to the need for an aligned definition and consistent terminology around QSP, yet highlight the broad applicability and benefits preclinical QSP modeling is currently delivering.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Design
Drug Discovery / methods*
Drug Discovery / standards
Drug Evaluation, Preclinical / standards*
Drug Industry
Humans
Models, Biological
Pharmacology, Clinical / methods*
Pharmacology, Clinical / standards
Surveys and Questionnaires